MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 466144 | Name: Alalevonadifloxacin mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alalevonadifloxacin mesylate is a novel anti-MRSA antibacterial agent, targeting infections caused by Gram-positive bacteria.

Chemical Structure

Alalevonadifloxacin mesylate
Alalevonadifloxacin mesylate
CAS#948895-94-1 (mesylate)

Theoretical Analysis

MedKoo Cat#: 466144

Name: Alalevonadifloxacin mesylate

CAS#: 948895-94-1 (mesylate)

Chemical Formula: C23H30FN3O8S

Exact Mass: 527.1738

Molecular Weight: 527.56

Elemental Analysis: C, 52.36; H, 5.73; F, 3.60; N, 7.97; O, 24.26; S, 6.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
396132-82-4 (HCl) 706809-20-3 (free base) 948895-94-1 (mesylate salt)
Synonym
Alalevonadifloxacin mesylate; Alalevonadifloxacin HCl; Alalevonadifloxacin; WCK2349; WCK 2349; WCK-2349;
IUPAC/Chemical Name
(S)-8-(4-((L-alanyl)oxy)piperidin-1-yl)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid compound with methanesulfonic acid (1:1)
InChi Key
QFROQFYGNZZJJU-FXMYHANSSA-N
InChi Code
InChI=1S/C22H26FN3O5.CH4O3S/c1-11-3-4-14-18-15(20(27)16(21(28)29)10-26(11)18)9-17(23)19(14)25-7-5-13(6-8-25)31-22(30)12(2)24;1-5(2,3)4/h9-13H,3-8,24H2,1-2H3,(H,28,29);1H3,(H,2,3,4)/t11-,12-;/m0./s1
SMILES Code
O=C(C(C1=O)=CN2[C@@H](C)CCC3=C2C1=CC(F)=C3N4CCC(OC([C@@H](N)C)=O)CC4)O.OS(=O)(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 527.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. Bioorg Med Chem Lett. 2021 Dec 15;54:128432. doi: 10.1016/j.bmcl.2021.128432. Epub 2021 Oct 30. PMID: 34757217. 2: Ahirrao V, Rane V, Patil K, More K, Jadhav R, Yeole R. Reverse-phase chiral high-performance liquid chromatography for separation of a diastereomer in alalevonadifloxacin: A novel antibacterial agent. Biomed Chromatogr. 2021 Jun;35(6):e5079. doi: 10.1002/bmc.5079. Epub 2021 Feb 7. PMID: 33527391. 3: Lautre C, Sharma S, Sahu JK. Chemistry, Biological Properties and Analytical Methods of Levonadifloxacin: A Review. Crit Rev Anal Chem. 2020 Dec 13:1-9. doi: 10.1080/10408347.2020.1855412. Epub ahead of print. PMID: 33307757. 4: Mamtora D, Saseedharan S, Rampal R, Joshi P, Bhalekar P, Ahdal J, Jain R. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital. J Lab Physicians. 2020 Dec;12(3):230-232. doi: 10.1055/s-0040-1720944. Epub 2020 Nov 23. PMID: 33268943; PMCID: PMC7684988. 5: Baliga S, Mamtora DK, Gupta V, Shanmugam P, Biswas S, Mukherjee DN, Shenoy S. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay. Indian J Med Microbiol. 2020 Jul-Dec;38(3 & 4):307-312. doi: 10.4103/ijmm.IJMM_20_307. PMID: 33154240. 6: Patil KR, Rane VP, Ahirrao VK, Yeole RD. Impurity Profiling of a Novel Anti- MRSA Antibacterial Drug: Alalevonadifloxacin. J Chromatogr Sci. 2020 Oct 26;58(10):951-960. doi: 10.1093/chromsci/bmaa068. PMID: 32932524. 7: Bakthavatchalam YD, Rao SV, Isaac B, Manesh A, Nambi S, Swaminathan S, Nagvekar V, Nangia V, John PV, Veeraraghavan B. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin- resistant Staphylococcus aureus agent levonadifloxacin: Therapeutic role in nosocomial and community infections. Indian J Med Microbiol. 2019 Oct- Dec;37(4):478-487. doi: 10.4103/ijmm.IJMM_20_34. PMID: 32436868. 8: Bakthavatchalam YD, Shankar A, Muniyasamy R, Peter JV, Marcus Z, Triplicane Dwarakanathan H, Gunasekaran K, Iyadurai R, Veeraraghavan B. Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. J Antimicrob Chemother. 2020 Aug 1;75(8):2156-2159. doi: 10.1093/jac/dkaa142. PMID: 32361727. 9: Chavan R, Zope V, Chavan N, Shaikh J, Patil K, Yeole R, Bhagwat S, Patel M. Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. Xenobiotica. 2020 Oct;50(10):1149-1157. doi: 10.1080/00498254.2020.1756007. Epub 2020 Apr 22. PMID: 32283993. 10: Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence. Drug Des Devel Ther. 2019 Dec 24;13:4351-4365. doi: 10.2147/DDDT.S229882. PMID: 31920285; PMCID: PMC6935279. 11: Appalaraju B, Baveja S, Baliga S, Shenoy S, Bhardwaj R, Kongre V, Dattatraya GS, Dhole T, Verma B, Mukherjee DN, Gupta S, Shanmugam P, Iravane J, Mishra SR, Barman P, Chopra S, Hariharan M, Surpam R, Pratap R, Joshi P, Khande H, Mane A, Jain R, Bhagwat S. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. J Antimicrob Chemother. 2020 Mar 1;75(3):600-608. doi: 10.1093/jac/dkz493. PMID: 31840170. 12: Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. Clin Transl Sci. 2019 Jan;12(1):47-52. doi: 10.1111/cts.12594. Epub 2018 Nov 27. PMID: 30369076; PMCID: PMC6342240. 13: Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R, Patel A, Bhatia A. Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02297-17. doi: 10.1128/AAC.02297-17. PMID: 29263070; PMCID: PMC5826115.